Finance Watch: Third Rock Raises $770m To Launch Up To 12 New Companies
Executive Summary
The VC firm known for its new company formation efforts will launch 10-12 biopharma, device and diagnostic ventures with its fifth fund. Also, EpimAb raises a $74m series B round, three more drug developers join the IPO queue and Amicus leads recent follow-on offerings.
You may also be interested in...
Finance Watch: 2019 Ended With Near-Record VC Financings, But Some Slowing Expected In 2020
Private Company Edition: VC deals fell short of the record-breaking level seen in 2018 and financings may slow a bit more in 2020. Also, UPMC and Frazier close new VC funds, and Emendo raises $61m for gene-editing platform.
Finance Watch: Summer Slowdown Nears Its End With Strategic Shifts And IPO Hopes
Merrimack's wind-down continues with an activist challenge, but investors approved the Vical/Brickell Biotech reverse merger. Also, the past month's IPO slump may reverse course and HiFiBiO's $67m Series C leads recent financings.
Deal Watch: Themis Leverages Measles Vector Platform In Collaboration With Merck & Co.
In its first big pharma deal, Austrian biotech will develop experimental vaccines for Merck against an undisclosed target. Innovent licenses Chinese rights to Lilly diabetes candidate, while Novartis gets option to Iconic’s preclinical ophthalmology program.
Need a specific report? 1000+ reports available
Buy Reports